It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green whileBMY’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 5 TA indicator(s) are bullish while BMY’s TA Score has 4 bullish TA indicator(s).
ABBV (@Pharmaceuticals: Major) experienced а +0.41% price change this week, while BMY (@Pharmaceuticals: Major) price change was -0.22% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.88%. For the same industry, the average monthly price growth was -3.23%, and the average quarterly price growth was -0.33%.
ABBV is expected to report earnings on Nov 03, 2023.
BMY is expected to report earnings on Oct 26, 2023.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
|ABBV||BMY||ABBV / BMY|
overvalued / fair valued / undervalued
PROFIT vs RISK RATING
PRICE GROWTH RATING
P/E GROWTH RATING
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMY's Valuation (3) in the Pharmaceuticals Major industry is in the same range as ABBV (15). This means that BMY’s stock grew similarly to ABBV’s over the last 12 months.
ABBV's Profit vs Risk Rating (7) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (59). This means that ABBV’s stock grew somewhat faster than BMY’s over the last 12 months.
ABBV's SMR Rating (18) in the Pharmaceuticals Major industry is in the same range as BMY (39). This means that ABBV’s stock grew similarly to BMY’s over the last 12 months.
ABBV's Price Growth Rating (45) in the Pharmaceuticals Major industry is in the same range as BMY (62). This means that ABBV’s stock grew similarly to BMY’s over the last 12 months.
ABBV's P/E Growth Rating (21) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (84). This means that ABBV’s stock grew somewhat faster than BMY’s over the last 12 months.
4 days ago41%
4 days ago69%
4 days ago44%
4 days ago53%
4 days ago70%
4 days ago57%
4 days ago59%
4 days ago54%
4 days ago58%
4 days ago51%
4 days ago62%
4 days ago48%
12 days ago55%
5 days ago57%
4 days ago48%
8 days ago54%
4 days ago40%
4 days ago66%
4 days ago56%
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with PFE. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then PFE could also see price increases.